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Recent trend in treatment of peripheral neuropathy
Tomihiro IMAI
Sapporo Medical University, School of Health Sciences, Department of Occupational Therapy
The pathological changes of polyneuropathy include generalized axonal loss and/or demyelination. On the 
other hand, mononeuropathy and mononeuropathy multiplex provide localized pathological changes in the 
peripheral nerves. Although the electrophysiological and histological findings are useful to determine the 
lesion, the peripheral neuropathy can be classified into several groups based on the time course (eg. acute, 
subacute, chronic) of the disease progression as well as the anatomical distribution. This editorial includes the 
characteristic features and differential diagnosis of the peripheral neuropathies such as axonal polyneuropathy, 
demyelinating polyneuropathy, neuronopathy, autonomic neuropathy and mononeuropathy. In addition, recent 
treatment trend is also described in diabetic neuropathy, toxic neuropathy, immune-mediated neuropathy and 
hereditary neuropathy.
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